The uncertain stance of the US President, Donald Trump, and the incidents of civil unrest could potentially impact the future of pharmaceutical companies. Although the ones receiving federal aid will be subjected to the dictum of distribution, the COVID pandemic has dented Trump's reputation that was initially built on his economy successes.